Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.
Case Library Membership
Search free — but unlock advanced filters to find every case involving a specific company or clause.
Already a member? Sign in →
Case Library Membership
inc. VAT
inc. VAT · cancel any time
Secure payment via Stripe
Need access for your team?
Company licences available for compliance teams, medical affairs, and training programmes.
Get a team quote →1,930 cases found
Complaint said an Ezetrol Pulse ad implying “New NICE” guidance was misleading vs NICE lipid guideline. Panel found headline clearly referred to…
A Lipitor journal ad cited economic modelling (“37%” vs “82%”) on cholesterol target attainment. PMCPA found the bold percentages misleading and not…
A NeoClarityn journal ad implied clinically supported anti-inflammatory action. PMCPA found it inconsistent with the SPC and misleading, ruling breaches of Clauses…
A pharmacist alleged a Crestor journal ad implied NICE cholesterol targets had been reduced and omitted first-line NICE advice. The Panel found…
A respiratory nurse complained about a sales manager’s personal Facebook/Instagram posts referencing a nurse KOL. Panel found one Instagram post in scope…
A pioglitazone journal ad implied CV event reduction as part of the product’s benefits and called a Takeda-funded meta-analysis “independent”. Breaches of…
A Xeomin leavepiece used a true “free from complexing proteins” fact alongside a horse chestnut visual, implying an unproven clinical advantage and…
Genus alleged Stiefel offered a PCT a cash rebate if Oilatum was reinstated on formulary (inducement to prescribe). Accounts conflicted and evidence…
Allergan materials and representative messaging suggested Xeomin was ~70% as potent as Botox based on animal assay data. PMCPA found the comparison…
A GP alleged a calcium/vitamin D service lacked proper practice authorisation and involved patient letters and promotion of Adcal-D3. The Panel found…
Two anonymous hospital HCPs alleged an AstraZeneca rep initiated discussion of unpublished/out-of-licence JUPITER (Crestor) data. Panel had concerns about internal briefings but…
Roche’s Bondronat hospital detail aid was ruled misleading for “innovative” branding, renal safety wording, implied infusion-time comparisons, small-sample resource claims and ASCO…
Pfizer admitted a Lipitor journal ad previously ruled in breach reappeared in Practitioner. Panel found breach of Clause 25 (undertaking). Appeal overturned…
A GP practice complained about an Otsuka representative’s unprofessional email (sent from work email) containing disparaging comments about GPs. Breaches were found…
Anonymous complaint alleged Merck Serono encouraged off-licence promotion of Pergoveris via internal emails targeting Menopur IVF/ICSI cycles. Panel found emails unclear on…
Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.
